Molecular characteristics of glioblastoma with 1p/19q co-deletion
- 27 June 2012
- journal article
- Published by Springer Nature in Brain Tumor Pathology
- Vol. 29 (3) , 148-153
Abstract
Recent developments in molecular analysis have revealed genetic alterations in human gliomas. Loss of heterozygosity (LOH) is a critical molecular marker for classification of human glioma, and is useful for predicting outcome. Our previous LOH study identified a small subgroup of glioblastoma (GBM), with 1p/19q co-deletion, with a favorable clinical outcome. In this study, we investigated molecular pathological features of eight GBM with 1p/19q co-deletion compared with “classic” GBM and anaplastic oligodendroglioma (AO). We estimated EGFR gene amplification, EGFRvIII expression, CDKN2A (p16) homozygous deletion, and isocitrate dehydrogenase 1/2 (IDH1/2) gene mutations. We also conducted an analysis of the expression of proneural genes (DLL3, OLIG2, SOX2). On histopathological review, only one GBM was diagnosed as glioblastoma with oligodendroglioma component (GBMO). Loss of chromosomes 10 and 17p is common, and neither IDH1/2 mutations nor EGFRvIII expression were detected in GBM with 1p/19q co-deletion. The expression profile revealed high expression of the OLIG2 gene in this subgroup. High expression of proneural gene OLIG2 without EGFRvIII expression may be associated with a favorable clinical outcome; however, IDH1/2 gene status and the extent of LOH regions may indicate that this small subgroup of GBM is a distinct genetic subgroup from oligodendroglial tumors.Keywords
This publication has 28 references indexed in Scilit:
- Genetic alterations and signaling pathways in the evolution of gliomasCancer Science, 2009
- Genetic Pathways to Primary and Secondary GlioblastomaThe American Journal of Pathology, 2007
- A t(1;19)(q10;p10) Mediates the Combined Deletions of 1p and 19q and Predicts a Better Prognosis of Patients with OligodendrogliomaCancer Research, 2006
- Identification of der(1;19)(q10;p10) in Five Oligodendrogliomas Suggests Mechanism of Concurrent 1p and 19q LossJournal of Neuropathology & Experimental Neurology, 2006
- Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III TrialJournal of Clinical Oncology, 2006
- Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402Journal of Clinical Oncology, 2006
- Two types of chromosome 1p losses with opposite significance in gliomasAnnals of Neurology, 2005
- Glioma ClassificationThe American Journal of Pathology, 2001
- Loss of Heterozygosity on Chromosome 19 in Secondary GlioblastomasJournal of Neuropathology & Experimental Neurology, 2000
- Specific Genetic Predictors of Chemotherapeutic Response and Survival in Patients With Anaplastic OligodendrogliomasJNCI: Journal of the National Cancer Institute, 1998